<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Lawyers Collective</title>
	<atom:link href="http://www.lawyerscollective.org/feed" rel="self" type="application/rss+xml" />
	<link>http://www.lawyerscollective.org</link>
	<description></description>
	<lastBuildDate>Tue, 21 May 2013 15:47:32 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	
		<item>
		<title>Supreme Court to decide on women’s right to dance in bars</title>
		<link>http://www.lawyerscollective.org/updates/supreme-court-decide-womens-dance-bars.html</link>
		<comments>http://www.lawyerscollective.org/updates/supreme-court-decide-womens-dance-bars.html#comments</comments>
		<pubDate>Tue, 14 May 2013 07:43:33 +0000</pubDate>
		<dc:creator>Lawyers Collective</dc:creator>
				<category><![CDATA[Updates]]></category>
		<category><![CDATA[appeal]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lawyers Collective]]></category>
		<category><![CDATA[Women]]></category>

		<guid isPermaLink="false">http://www.lawyerscollective.org/?p=1738</guid>
		<description><![CDATA[9 May 2013, New Delhi: The Supreme Court today reserved its decision on the constitutionality of the ban on dance performances in bars in Maharashtra imposed under the Bombay Police (Amendment) Act of 2005. Introduced in August 2005, section 33A of the Bombay Police Act prohibited ‘any type of dancing’ in an “eating house, permit]]></description>
		<wfw:commentRss>http://www.lawyerscollective.org/updates/supreme-court-decide-womens-dance-bars.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why Novartis case will help innovation</title>
		<link>http://www.lawyerscollective.org/news/novartis-case-innovation.html</link>
		<comments>http://www.lawyerscollective.org/news/novartis-case-innovation.html#comments</comments>
		<pubDate>Tue, 16 Apr 2013 09:19:53 +0000</pubDate>
		<dc:creator>Lawyers Collective</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[patent]]></category>

		<guid isPermaLink="false">http://www.lawyerscollective.org/?p=1726</guid>
		<description><![CDATA[The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board’s decision to deny patent protection to Novartis’s application covering a beta crystalline form of imatinib —the medicine Novartis brands as Glivec, and which]]></description>
		<wfw:commentRss>http://www.lawyerscollective.org/news/novartis-case-innovation.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India’s patent case victory rattles Big Pharma</title>
		<link>http://www.lawyerscollective.org/news/indias-patent-case-victory-rattles-big-pharma.html</link>
		<comments>http://www.lawyerscollective.org/news/indias-patent-case-victory-rattles-big-pharma.html#comments</comments>
		<pubDate>Tue, 16 Apr 2013 09:16:43 +0000</pubDate>
		<dc:creator>Lawyers Collective</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[appeal]]></category>
		<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[patent]]></category>

		<guid isPermaLink="false">http://www.lawyerscollective.org/?p=1724</guid>
		<description><![CDATA[Will India, the world’s biggest provider of low-cost generic medicines, be the pariah or the pioneer of the pharmaceutical world? There is renewed focus on this thorny question in the wake of India’s Supreme Court’s dismissal of Swiss pharma giant Novartis AG’s appeal for a patent for its cancer drug imatinib marketed as Glivec (Gleevec]]></description>
		<wfw:commentRss>http://www.lawyerscollective.org/news/indias-patent-case-victory-rattles-big-pharma.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Novartis Ruling Reverberates Past India&#8217;s Borders</title>
		<link>http://www.lawyerscollective.org/news/novartis-ruling-reverberates-indias-borders.html</link>
		<comments>http://www.lawyerscollective.org/news/novartis-ruling-reverberates-indias-borders.html#comments</comments>
		<pubDate>Fri, 12 Apr 2013 12:13:58 +0000</pubDate>
		<dc:creator>Lawyers Collective</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Gleevec]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[patent]]></category>

		<guid isPermaLink="false">http://www.lawyerscollective.org/?p=1722</guid>
		<description><![CDATA[India&#8217;s Supreme Court says drug maker Novartis can&#8217;t hold onto its patent for the pricey cancer drug Gleevec simply by tweaking its chemical formula. That means generic drug makers can keep making a form of the drug at a tenth of Novartis&#8217;s price. Consumer advocates call it a major advance for access to generic drugs.]]></description>
		<wfw:commentRss>http://www.lawyerscollective.org/news/novartis-ruling-reverberates-indias-borders.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India’s Patently Wise Decision</title>
		<link>http://www.lawyerscollective.org/news/indias-patently-wise-decision.html</link>
		<comments>http://www.lawyerscollective.org/news/indias-patently-wise-decision.html#comments</comments>
		<pubDate>Fri, 12 Apr 2013 12:13:00 +0000</pubDate>
		<dc:creator>Lawyers Collective</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Cancer]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[patent]]></category>

		<guid isPermaLink="false">http://www.lawyerscollective.org/?p=1720</guid>
		<description><![CDATA[The Indian Supreme Court’s refusal to uphold the patent on Gleevec, the blockbuster cancer drug developed by the Swiss pharmaceutical giant Novartis, is good news for many of those in India suffering from cancer. If other developing countries follow India’s example, it will be good news elsewhere, too: more money could be devoted to other]]></description>
		<wfw:commentRss>http://www.lawyerscollective.org/news/indias-patently-wise-decision.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The hypocrisy of Novartis</title>
		<link>http://www.lawyerscollective.org/news/hypocrisy-novartis.html</link>
		<comments>http://www.lawyerscollective.org/news/hypocrisy-novartis.html#comments</comments>
		<pubDate>Fri, 12 Apr 2013 12:10:54 +0000</pubDate>
		<dc:creator>Lawyers Collective</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Cancer]]></category>

		<guid isPermaLink="false">http://www.lawyerscollective.org/?p=1718</guid>
		<description><![CDATA[The MNC had earned a billion dollars from its cancer drug in the first year and now seems to be living off it; pharma corporations tend to become extortionists out to control patients and their life. The week gone by was a strange week of events and non-events. Two non-events were the repeated anointing of]]></description>
		<wfw:commentRss>http://www.lawyerscollective.org/news/hypocrisy-novartis.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Attack on affordable medicines continues in EU-India trade negotiations</title>
		<link>http://www.lawyerscollective.org/updates/attack-affordable-medicines-continues-eu-india-trade-negotiations.html</link>
		<comments>http://www.lawyerscollective.org/updates/attack-affordable-medicines-continues-eu-india-trade-negotiations.html#comments</comments>
		<pubDate>Fri, 12 Apr 2013 07:48:14 +0000</pubDate>
		<dc:creator>Lawyers Collective</dc:creator>
				<category><![CDATA[Press Release]]></category>
		<category><![CDATA[Updates]]></category>
		<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Constitution]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[patent]]></category>
		<category><![CDATA[Positive]]></category>
		<category><![CDATA[right to health]]></category>
		<category><![CDATA[section 3(d)]]></category>
		<category><![CDATA[Top]]></category>

		<guid isPermaLink="false">http://www.lawyerscollective.org/?p=1713</guid>
		<description><![CDATA[Attack on affordable medicines continues in EU-India trade negotiations Health groups rally in Delhi as protests spread across the developing world  10 April, 2013, New Delhi­- Thousands of people living with HIV, cancer patient groups &#38; public health activists rallied on the streets of Delhi today calling on the Indian government to reject the EU&#8217;s]]></description>
		<wfw:commentRss>http://www.lawyerscollective.org/updates/attack-affordable-medicines-continues-eu-india-trade-negotiations.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Apex court right to reject Novartis&#8217;s attempt</title>
		<link>http://www.lawyerscollective.org/updates/apex-court-reject-novartiss-attempt.html</link>
		<comments>http://www.lawyerscollective.org/updates/apex-court-reject-novartiss-attempt.html#comments</comments>
		<pubDate>Thu, 04 Apr 2013 06:46:21 +0000</pubDate>
		<dc:creator>Lawyers Collective</dc:creator>
				<category><![CDATA[Updates]]></category>
		<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lawyers Collective]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[patent]]></category>
		<category><![CDATA[right to health]]></category>
		<category><![CDATA[section 3(d)]]></category>

		<guid isPermaLink="false">http://www.lawyerscollective.org/?p=1704</guid>
		<description><![CDATA[Novartis  threat that it would not introduce new medicines in India after the verdict is hollow, says Anand Grover. While the patients and the generic companies have rejoiced over the Supreme Court’s verdict in the Novartis case rejecting the patent for its drug Gleevec, Novartis itself has threatened that it will not register any new]]></description>
		<wfw:commentRss>http://www.lawyerscollective.org/updates/apex-court-reject-novartiss-attempt.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
